Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

por Ortiz-Maldonado, Valentín, Rives, Susana, Español-Rego, Marta, Alonso-Saladrigues, Anna, Montoro, Mercedes, Magnano, Laura, Giné, Eva, Pascal, Mariona, Díaz-Beyá, Marina, Castella, Maria, Català, Albert, Faura, Anna, Rodríguez-Lobato, Luis Gerardo, Oliver-Caldes, Aina, Martínez-Roca, Alexandra, Rovira, Montserrat, González-Navarro, E Azucena, Ortega, Juan Ramón, Cid, Joan, Lozano, Miquel, Garcia-Rey, Enric, Fernández, Sara, Castro, Pedro, Jordan, Iolanda, Villamor, Neus, Aymerich, Marta, Torrebadell, Montserrat, Deyà, Àngela, Fernández de Larrea, Carlos, Benitez-Ribas, Daniel, Trias, Esteve, Varea, Sara, Calvo, Gonzalo, Esteve, Jordi, Urbano-Ispizua, Alvaro, Juan, Manel, Delgado, Julio
Publicado 2021